Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Robert Valesky"'
Autor:
William D. Hanley, Yali Zhu, William L. Marshall, Luzelena Caro, Hwa-Ping Feng, Eric Mangin, Deborah Panebianco, Xiaobi Huang, Robert Valesky, Jennifer Talaty, Monika Martinho, Joan R. Butterton, Patricia Jumes, Christine Fandozzi, Zifang Guo, Wendy W. Yeh, Marian Iwamoto
Publikováno v:
Clinical Pharmacology in Drug Development. 8:962-970
Treatment of individuals coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) requires careful consideration of potential drug-drug interactions. We evaluated the pharmacokinetic interaction of the direct-acting antiviral ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a42966b426c387ac34b77c65f59795
https://doi.org/10.1002/cpdd.701
https://doi.org/10.1002/cpdd.701
Autor:
Patricia Jumes, Lynn Webster, Zifang Guo, Wendy W. Yeh, Luzelena Caro, Pavan Vaddady, Monika Martinho, Dennis Wolford, Deborah Panebianco, Marian Iwamoto, Hwa-Ping Feng, Christina Reitmann, Iain Fraser, Joan R. Butterton, Robert Valesky, William L. Marshall, Fang Liu
Publikováno v:
Clinical and Translational Science. 11:553-561
We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK-8742-P010 and MK-5172-P030) in non-hepatitis C virus (HCV)-infected participants on methadone maintenance therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4041f4cac0090471d4c66213680894b4
https://doi.org/10.1111/cts.12564
https://doi.org/10.1111/cts.12564
Autor:
William L. Marshall, Luzelena Caro, Jocelyn Gilmartin, Dennis Wolford, Zifang Guo, April M. Barbour, Monika Martinho, Christina Reitmann, Lynn Webster, Pavan Vaddady, Deborah Panebianco, Iain Fraser, Wendy W. Yeh, Marian Iwamoto, Fang Liu, Patricia Jumes, Robert Valesky, Joan R. Butterton, Hwa-Ping Feng
Publikováno v:
Clinical and Translational Science. 11:562-572
The aims of these phase I trials were to evaluate the pharmacokinetic interaction between elbasvir (EBR) or grazoprevir (GZR) and buprenorphine/naloxone (BUP/NAL). Trial 1 was a single-dose trial in healthy participants. Trial 2 was a multiple-dose t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e324372a9b0b7cf69723f4699e0b4e4c
https://doi.org/10.1111/cts.12565
https://doi.org/10.1111/cts.12565
Autor:
Wendy W. Yeh, Iain P. Fraser, Christine Fandozzi, Jennifer Talaty, Anna Mitselos, Marian Iwamoto, Xiaoyan Chu, Monika Martinho, Corinne Vandermeulen, Luzelena Caro, Xiaobi Huang, Zifang Guo, Jean Francois Denef, Katherine Dunnington, William D. Hanley, Deborah Panebianco, Jan de Hoon, Inge De Lepeleire, Joan R. Butterton, Hwa-Ping Feng, Lihong Du, Patricia Jumes, William L. Marshall, Robert Valesky
The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437fd6dfa5132f3e6a6fda32702d0e3a
https://lirias.kuleuven.be/handle/123456789/635688
https://lirias.kuleuven.be/handle/123456789/635688
Autor:
Zifang Guo, Christine Fandozzi, Luzelena Caro, Matthew L. Rizk, Robert Valesky, Deborah Panebianco, Daniel P. Dreyer, Monika Martinho, Wendy W. Yeh, Marian Iwamoto, Hwa-Ping Feng, Dennis Wolford
Publikováno v:
Clinical pharmacology in drug developmentReferences. 8(7)
Treatment of individuals coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) requires careful consideration of potential drug-drug interactions. The pharmacokinetic interaction of the HCV fixed-dose combination treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e89784c791bd2345ae4814e0d430417
https://pubmed.ncbi.nlm.nih.gov/31173673
https://pubmed.ncbi.nlm.nih.gov/31173673
Autor:
Hwa-Ping, Feng, Zifang, Guo, Luzelena, Caro, William L, Marshall, Fang, Liu, Deborah, Panebianco, Pavan, Vaddady, Christina, Reitmann, Patricia, Jumes, Dennis, Wolford, Iain, Fraser, Robert, Valesky, Monika, Martinho, Joan R, Butterton, Marian, Iwamoto, Lynn, Webster, Wendy W, Yeh
Publikováno v:
Clinical and Translational Science
We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK‐8742‐P010 and MK‐5172‐P030) in non‐hepatitis C virus (HCV)‐infected participants on methadone mainte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1956c4bacf8d512fb1913d5414f9c13f
https://pubmed.ncbi.nlm.nih.gov/30040872
https://pubmed.ncbi.nlm.nih.gov/30040872
Autor:
S. Aubrey Stoch, Luzelena Caro, Iain P. Fraser, Xiaoyan Chu, Cynthia Dempsey, Scott Rasmussen, Xiaoxin Cai, Robert Houle, Grace Chan, Prajakti A. Kothare, Stephanie O. Klopfer, Robert Valesky, Raymond Evers, Thomayant Prueksaritanont
Publikováno v:
British Journal of Clinical Pharmacology. 78:587-598
Aims Rosuvastatin and pitavastatin have been proposed as probe substrates for the organic anion-transporting polypeptide (OATP) 1B, but clinical data on their relative sensitivity and selectivity to OATP1B inhibitors are lacking. A clinical study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abbeedd27a8c3fc075ba548affce4664
https://doi.org/10.1111/bcp.12377
https://doi.org/10.1111/bcp.12377
Publikováno v:
Journal of Chromatography B. 877:1465-1471
Telcagepant (MK-0974) is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical development. Results from phases II and III clinical trials have suggested that telcagepant is effective for migraine tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b8e3b1fa5800d33f16b50e4ee9a823
https://doi.org/10.1016/j.jchromb.2009.03.019
https://doi.org/10.1016/j.jchromb.2009.03.019
Autor:
Thomayant, Prueksaritanont, Xiaoyan, Chu, Raymond, Evers, Stephanie O, Klopfer, Luzelena, Caro, Prajakti A, Kothare, Cynthia, Dempsey, Scott, Rasmussen, Robert, Houle, Grace, Chan, Xiaoxin, Cai, Robert, Valesky, Iain P, Fraser, S Aubrey, Stoch
Publikováno v:
British journal of clinical pharmacology. 78(3)
Rosuvastatin and pitavastatin have been proposed as probe substrates for the organic anion-transporting polypeptide (OATP) 1B, but clinical data on their relative sensitivity and selectivity to OATP1B inhibitors are lacking. A clinical study was ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::201f43fa6b85cf167836c452397d361e
https://pubmed.ncbi.nlm.nih.gov/24617605
https://pubmed.ncbi.nlm.nih.gov/24617605
Autor:
Kenneth C. Lasseter, K Gottesdiener, L Liu, Amy O. Johnson-Levonas, Robert Valesky, A Laurent, Elizabeth Migoya, G Murphy, David Hreniuk, Brad Roadcap, N Matthews, Bingming Yi, John F. Paolini, Donald G. Musson, Arthur J. Bergman, J Gambale, Jamie J. Zhao, M Groff, Teddy Kosoglou, K Riffel, Paul Statkevich
Publikováno v:
International journal of clinical pharmacology and therapeutics. 44(2)
Objective: To assess the bioequivalence of an ezetimibe/simvastatin (EZE/SIMVA) combination tablet compared to the coadministration of ezetimibe and simvastatin as separate tablets (EZE + SIMVA). Methods: In this open-label, randomized, 2-part, 2-per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e1ee683f2bcf674ddd1e95bf73d58d2
https://pubmed.ncbi.nlm.nih.gov/16502768
https://pubmed.ncbi.nlm.nih.gov/16502768